Home
IMTX

IMTX

Immatics N.V.

as of 12-05-2025 3:46pm EST

$10.34

$1.54

-12.96%

Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Chart Type:

Time Range:

Founded:	N/A	Country:	Germany
Employees:	N/A	City:	N/A
Market Cap:	1.3B	IPO Year:	N/A
Target Price:	$19.25	AVG Volume (30 days):	657.4K
Analyst Decision:	Strong Buy	Number of Analysts:	5
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-1.17	EPS Growth:	N/A
52 Week Low/High:	$3.30 - $12.41	Next Earning Date:	11-17-2025
Revenue:	$99,445,031	Revenue Growth:	-26.62%
Revenue Growth (this year):	-75.45%	Revenue Growth (next year):	24.39%

AI-Powered IMTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 74.15%

74.15%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full IMTX Forecast & Prediction with Hourly Data

Compare IMTX vs Leading Stocks

See how IMTX stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free IMTX Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.